Chemed Corp (NYSE:CHE) reported an insider sale by its president and chief executive officer, Kevin J. McNamara, who sold 1,500 shares of company stock on March 27, 2026, for total proceeds of roughly $554,055.
Documentation filed on a Form 4 with the Securities and Exchange Commission shows the stock was disposed of at a weighted average price of $369.37 per share. Individual sale prices recorded in the filing ranged from $365.76 to $373.24. After completing the transaction, McNamara retained direct ownership of 92,219 shares of Chemed.
The sale occurred while Chemed's share price was trading close to its 52-week low of $365.20 and following a 39% decline over the past year. An InvestingPro analysis, cited in available disclosures, characterized the stock as appearing undervalued at current levels.
Separately, Chemed disclosed financial results for the fourth quarter of 2025 that fell short of consensus forecasts. The company reported earnings per share of $6.42, below the projected $7.07 figure. Revenue for the quarter was $639.34 million, compared with an expected $658.97 million.
Those quarterly shortfalls and related concerns about operational profitability prompted RBC Capital to lower its rating on Chemed, moving the stock from Outperform to Sector Perform. RBC's decision was described as primarily linked to uncertainties around margins at Chemed's Roto-Rooter division. At the same time, the research note highlighted favorable momentum within Chemed's VITAS hospice segment, with particular strength noted in Florida.
Investors and market participants have focused on these developments amid the share price weakness and the insider sale. The combination of a senior executive sale, earnings that missed estimates on both the earnings and revenue lines, and an analyst downgrade has drawn attention from the investment community.
Context for readers: The filing details, the quarter's financial metrics, the RBC rating change, and the commentary about business segments are taken from public disclosures and the company's recent reporting. No additional forecasts or forward-looking statements are included beyond what was reported.